The efficacy of pivmecillinam in oral step-down treatment in hospitalised patients with E. coli bacteremic urinary tract infection; a single-arm, uncontrolled treatment study

Table 3 Clinical and microbiological characteristics at baseline of 50 patients with E. coli bacteremic UTI—Per-protocol population (n = 50)

Baseline characteristics	Result
Age, median (range), y	67 (34–87)
Women	28 (56.0)
Charlson comorbidity index—CCI, mean	1.8
CCI < 3	39 (73.6)
CCI > 5	4 (7.5)
Diabetes mellitus	11 (22.0)
Cancer (lymphoma/leukemia/solid tumour)	7 (13.2)
Indwelling urinary catheter	8 (15.1)
BMI^a, median (range)	26.4 (16.6–38.1)
Positive blood culture on admission	50 (100.0)
Positive blood culture on day 3	1 (2.0)
E. coli as causative agent	50 (100.0)
Parenteral antibiotic day 0–3
Ampicillin + gentamicin	27 (54.0)
Cefotaxime	7 (14.0)
Piperacillin/tazobactam	0 (0.0)
Ampicillin	1 (2.0)
Combination of above	15 (30.0)
Q-SOFA^b ≥ 2 on admission	2 (4.0)
SIRS^c ≥ 3 on admission	31 (62.0)
C-reactive protein on admission, mg/L, median (range)	163 (1.8–349.0)
Procalcitonin on admission, mcg/L, median (range)	1.0 (< 0.1–56.1)
White cell count on admission, 10⁹ × cells/L, median (range)	14.5 (4.7–137.0)
Neutrophils on admission, 10⁹ × cells/L, median (range)	11.7 (1.9–23.1)
E-GFR^d on admission, median (range)	59.5 (23–107)
Body temperature ≥ 39.0 °C	20 (40.0)
Symptoms of UTI on admission^e	29 (58.0)

Microbiology	Result
Positive urine culture on admission (E. coli > 10³ CFU^f/mL)	45 (90.0)
Non-wild type (mecillinam inhibition zone 16–19 mm)	4 (8.0)
ESBL^g-producing	2 (4.0)
Resistant to ciprofloxacin	6 (12.0)
Resistant to TMP–SMX^h	11 (22.0)
Resistant to gentamicin	1 (2.0)
Resistant to cefotaxime	2 (4.0)
Resistant to ampicillin	18 (36.0)
Resistant to meropenem	0 (0.0)
Resistant to piperacillin/tazobactam	3 (6.0)

Data are number (%), unless otherwise indicated
^aBody Mass Index, ^bQuick Sepsis-related Organ Failure Assessment, ^cSystemic Inflammatory Response Syndrome, ^dEstimated Glomerular Filtration Rate, ^eOne of the following: dysuria, pollakisuria, hematuria, suprapubic pain or abdominal pain, ^fColony Forming Units, ^gExstended Spectrum Beta-Lactamases, ^hTrimethoprim sulfamethoxazole

ISSN: 1471-2334